Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Lung 200: Avelumab vs Docetaxel in Platinum-Treated NSCLC
NCT02395172Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Mar 2015
- Primary completion
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
A Phase 3 trial of avelumab in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Mar 2015; status: completed.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02395172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395172.